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Summary
Background: Epilepsy is a frequent condition in persons with intellectual disability
and is more often difficult to treat than in the average population. Seizure freedom is
the primary therapeutic goal which has important implications for the patient’s
quality of life. The aim of this study was to find out which antiepileptic therapy
regimens (monotherapy or combination therapy) are effective in achieving this goal in
intellectually disabled epilepsy patients. We were especially interested in the impact
of the new antiepileptic drugs (AEDs) which were introduced during the past decade.
Method: We investigated retrospectively the antiepileptic regimens on which the
resident patients of a large epilepsy centre (as a rule with additional intellectual
disabilities of different degrees) were seizure free in 2002. Information on antiepi-
leptic medication and seizure frequency was taken out of the individual case
documentation. It was also determined whether seizure free patients had already
been seizure free in 1992.
Results: Two hundred and forty out of 675 patients (35,6%) with epilepsy were seizure
free. The proportion of seizure freedom was 43,7% in patients with borderline
intelligence, 39,2% in mild, 33,2% in moderate, 31,9% in severe, and 21,9% in profound
intellectual disability. One hundred and twenty-two (50,8%) seizure free patients
were on monotherapy; 53 of them were on CBZ (PB: 34, VPA: 25, PHT: 7, LTG: 3).
Ninety-three patients (38,7%) were on duotherapies, CBZ/PB (27 patients), PB/PHT
(17), and LTG/VPA (14) being the commonest. Of 18 (7,5%) triple therapies, LTG/PB/
VPA (4 patients) was the commonest. Taken together, the five most frequent ther-
apeutic regimens were CBZ monotherapy, PB monotherapy, CBZ/PB, VPA monother-
apy and PB/PHT (a clear preponderance of classic AEDs).* Corresponding author. Tel.: +49 5211442829; fax: +49 5211444736.
E-mail address: Aerztlicher-Dienst@t-online.de (B. Huber).
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382 B. Huber et al.A distinction was made between ‘‘old seizure free’’ (seizure free already in 1992)
and ‘‘new seizure free’’ (in 1992 still seizures) patients. In the 132 old seizure free
patients the classic AEDs prevailed again, monotherapies with CBZ, PB and VPA being
the most frequent regimens. In comparison, in the 78 new seizure free1 patients the
novel combination LTG/VPA was the third most frequent, after the classic regimens
CBZ/PB and CBZ; PB monotherapies were rare.
Conclusion: In a majority of intellectually disabled patients with epilepsy (including
those who became seizure free since 1992), complete seizure control has been
achieved by monotherapy or duotherapy with classic AEDs. Of the new AEDs LTG
in combination with VPA appears to be an important innovation.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Epilepsy is a frequent condition in persons with
intellectual disability1 and is more often difficult
to treat than in the average population.2 The main
therapeutic goal is complete seizure control; it has
major implications for the patient’s quality of life
and reduces associated morbidity and mortality.3
Whereas monotherapy is the accepted gold stan-
dard in antiepileptic therapy, a number of patients
need a combination of (mostly two) drugs. As a
consequence of the introduction of more than half
a dozen new antiepileptic drugs (AEDs) during the
last ten years, the number of possible combinations
has increased considerably. An unsolved problem is
the paucity of data regarding useful synergistic
combinations. It is a common recommendation to
combine drugs with different rather than with simi-
lar mechanisms of action but this recommendation
lacks empirical confirmation.
Stephen and Brodie4 followed a surprisingly
straightforward way to determine effective combi-
nations in their patients: They filtered seizure free
patients on combination therapy out of their exten-
sive database and thus found LTG/VPA,2 PB/PHT,
CBZ/GBP, and CBZ/VPA to be the most successful
combinations. Although this approach is far from
allowing definite conclusions we were fascinated by
its pragmatism and decided to undertake a similar
investigation in inpatients with epilepsy and intel-
lectual disability. Our aim was to determine ther-
apeutic regimens (monotherapy as well as
combination therapy) on which patients were sei-
zure free. We also wanted to find out to what degree
the new AEDs have contributed to achieving seizure
freedom in intellectually disabled patients.1 The remaining were admitted to the organisation between
1992 and 2002.
2 Abbreviations of AEDs: CBZ: carbamazepine; GBP: gabapen-
tin; LEV: levetiracetam; LTG: lamotrigine; OCBZ: oxcarbazepine;
PB: phenobarbital; PHT: phenytoin; TPM: topiramate; VPA:
valproate.Materials and methods
The residential department of the Bethel epilepsy
centre is a large organisation which provides long
term care for patients with epilepsy and different
degrees of intellectual and/or physical disabilities
(from borderline intelligence to profoundly multi-
handicapped). A large proportion of the resident
population has been living there for decades while
others have been admitted more recently. Many of
them suffer from difficult-to-treat epilepsies. Our
investigation covers nearly the whole institution
located near the centre of the city of Bielefeld
excluding only two residences which have a differ-
ent clientele.
Long-term antiepileptic treatment has been car-
ried out by the physicians of the integrated Bethel
medical service (mostly neurologists; all with spe-
cial experience in the diagnosis and treatment of
epilepsy). Antiepileptic therapy has always aimed to
achieve seizure freedom whenever possible or at
least to reach a balance between the best possible
seizure control and a minimum of side effects.
Information on the diagnosis of epilepsy (recur-
rent unprovoked seizures) and epileptic syndrome
(based on seizure descriptions and EEG findings,
according to the International League Against Epi-
lepsy ILAE classification)5 was taken from the indi-
vidual case histories. Information on antiepileptic
medication in 2002 was extracted from the current
case documentation. Seizure charts have been kept
for decades for every resident patient in order to
record all seizures observed in the residential homes
and also in the workshops or day centres; they were
used for information on seizure frequency. Patients
were denoted as completely seizure free (no seizure
at all in 2002) or nearly seizure free (compatible
with one uncomplicated seizure during the whole
year; or with one or two seizures because of acute
disease or forgotten medication; or with isolated
auras). Medication was mostly stable throughout the
whole year 2002; if not, certain rules were applied
to choose the key date (longest period of time with
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was determined; if more than one trough serum
levels: the latest).
As the organisation is specialising in epilepsy and
great efforts have been made for correct seizure
documentation in all resident patients it can be
assumed the seizure documentation was as accurate
as possible.
In those patients who were admitted to the
institution before 1992, seizure frequency in 1992
was evaluated in the same way.Figure 2 Duotherapies in seizure free patients.Results
Out of 867 residents, 677 had a diagnosis of epilepsy;
2 of these had to be excluded because frequent
additional psychogenic non-epileptic attacks ren-
dered the evaluation impossible. Of the remaining
675, 240 patients or 35,4% were seizure free in 2002
(182 patients completely seizure free, 58 nearly
seizure free; 122male, 118 female; all adults except
two adolescents). 122 (50,8%) of the seizure free
were on monotherapy, 114 (47,5%) were on combi-
nations of two or more AEDs (Table 1).
The monotherapies
Seizure free patients were on five different AEDs in
monotherapy, mainly the ‘‘classic’’ drugs (Fig. 1).Table 1 Number of AEDs per patient (seizure free).
Number of AEDs N
0 4a
1 122
2 93
3 18
4 3
a In these patients treatment had been discontinued
between 1992 and 2002.
Figure 1 Monotherapies in seizure free patients.The duotherapies
CBZ/PB was the most frequent duotherapy followed
by PB/PHT and LTG/VPA (Fig. 2).
The triple therapies
Within the small number of successful triple thera-
pies, only the combination LTG/PB/VPA occurred
more than twice (Fig. 3).Figure 3 Triple therapies in seizure free patients.
Figure 4 All therapeutic regimens.
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Figure 5 Therapeutic regimens in ‘‘old’’ versus ‘‘new’’ seizure free patients. ‘‘Old’’ seizure free: 132; ‘‘new’’ seizure
free: 78; rest: 30 (28: admission between 1992 and 2002; 1: late epilepsy developed after 1992, seizure free on therapy in
2002; 1: epilepsy surgery between 1992 and 2002).
Figure 6 The different therapeutic regimens in the
different degrees of intellectual disability.All kinds of therapeutic regimens
Fig. 4 gives an overview over the most frequent
therapeutic regimens in the seizure free.
The different therapeutic regimens in
‘‘old’’ versus ‘‘new’’ seizure free patients
A comparison was made between therapeutic regi-
mens in ‘‘old seizure free’’ (in 1992 already seizure
free) and ‘‘new seizure free’’ (in 1992 still seizures,
in 2002 seizure free) patients (Fig. 5).
The different therapeutic regimens in
different degrees of intellectual disability
The proportion of seizure free patients was 38 of 87
patients (43,7%) with borderline intelligence/learn-
ing difficulty,3 71 of 181 patients (39,2%) with mild,
75 of 226 patients (33,2%) with moderate, 46 of 144
patients (31,9%) with severe, and 7 of 32 patients
(21,9%) with profound intellectual disability. The
therapeutic regimens on which patients with differ-
ent degrees of intellectual disability were seizure
free are shown in Fig. 6.
The different therapeutic regimens in the
different epilepsy syndromes
The rates of seizure freedom were lowest in Len-
nox—Gastaut syndrome (4% of 50 patients) and in
multifocal epilepsies (11,5% of 52 patients) both
known to be difficult to treat types of epilepsy,
and highest in idiopathic generalised epilepsy
(58,3% of 24 patients), a relatively benign epileptic3 Borderline intelligence is usually defined by an IQ from 70 to
85. For the purpose of this study, we also included in this category
those patients with relevant learning difficulty due to severe
neuropsychological deficits like memory disorder etc.syndrome which is less common in intellectually
disabled patients. The other proportions were
38,0% of 308 patients with symptomatic or crypto-
genic focal epilepsy, 30,0% of 143 patients with
epilepsy with focal and generalised seizures,4 and
62,3% of 69 patients with symptomatic or crypto-
genic generalised epilepsy. Fig. 7 gives the thera-
peutic regimens on which patients with the
different syndromes were seizure free. The uneven
syndrome distribution and the small case numbers in
the less frequent syndromes make it difficult to
draw conclusions as for the efficacy of certain com-
binations in different syndromes.Discussion
We are aware that a retrospective study like this has
its limitations. Results obtained in a special popula-
tion cannot be generalised about an average epi-4 International League against Epilepsy subclass 3.1: ‘epilepsies
and syndromes undetermined whether they are focal or general-
ised — with both generalised and focal seizures’.
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Figure 7 The different therapeutic regimens in the
different epilepsy syndromes. sy/crypt foc epi: sympto-
matic or cryptogenic focal epilepsy; sy/crypt gen epi:
symptomatic or cryptogenic generalised epilepsy; foc + -
gen epi: epilepsies with both generalised and focal sei-
zures; idiopathic gen epi: idiopathic generalised epilepsy.lepsy population. Furthermore, the results do not
reflect exclusively the efficacy of different therapy
regimens, but also different therapy strategies or
prescribing habits. However, prescribing habits
emerge out of the physicians cumulating experi-
ences with their individual patients thus reflecting
the efficacy of different therapeutic approaches.
The views and wishes of family members or legal
representatives are among other factors which may
have exerted influence on AED treatment.
Main strengths may be the large case number and
first of all the excellent quality of data which was
guaranteed by the high proportion of trained staff
and the accuracy of long term seizure documenta-
tion which is carried out in all inpatients.
The proportion of seizure freedom was much
lower than the rates of approx. three quarter
usually reported in the literature and still lower
than the 56% in the Stephen and Brodie4 study. This
reflects the high rate of therapy resistance in intel-
lectually disabled epilepsy patients and also the
selected clientele of an epilepsy centre. The same
is for the rate of monotherapy which was lower than
one might expect. The figure of 78 new seizure free
patients in such a difficult-to-treat clientele points
out that continuing efforts to optimise antiepileptic
therapy are worthwhile.
A main message of the study may be not to forget
the classic AEDs. After a decade during which ther-
apy studies tended to focus on the new AEDs, and
our own efforts to improve the seizure situation of
the resident patients were also mainly based on the
new AEDs, wewere surprised to find out that still the
great majority of seizure free patients were on
classic AEDs. We first assumed this finding mightbe due to the high proportion of long term seizure
free patients. However, even more surprisingly,
even in the patients who became seizure free after
1992 classic therapeutic regimens such as CBZ/PB
and CBZ monotherapy prevailed (Fig. 5). On the
other hand, the combination LTG/VPA which is the
third frequent in the new seizure free is a major
innovation.
During the past years we have treated many of
the therapy-resistant resident patients with some of
the new AEDs. We have seen a 50% seizure reduction
in 28,8% on LTG,6 in 37,5% on TPM,7 and in 41,3% on
LEV.8 The number of seizure free patients however
was extremely low in these studies, a fact which is in
concordance with the results presented here.
The usefulness of the combination LTG/VPA in
intellectually disabled patients has been stressed by
other workers too.4,9
The minor role of new AEDs, apart from LTG, may
be due to diverse reasons. In our experience the
efficacy of GBP is low in the difficult-to-treat epi-
lepsy of intellectually disabled patients.10 TPM
appears to be more toxic in disabled patients than
otherwise reported.7 LEV has been marketed only
recently (autumn 2000 in Germany) and its broader
use may be a question of time. It is much more
difficult to explain why OCBZ is nearly not found in
successful therapy regimens. One possible reason
might be that OCBZ which has metabolic advantages
over CBZ was more often administered (e.g. repla-
cing CBZ) with the aim of better tolerability rather
than optimising seizure frequency.
Although there is no doubt that there has been
some progress for the intellectually disabled epi-
lepsy patient through the new AEDs, seizure free-
dom, the main therapeutic goal, has been
accomplished for the main part by the classic AEDs
in a sample of patients with chronic epilepsies and
intellectual disability residing in a large epilepsy
centre. Even in the patients who have become
seizure free since 1992 (within the decade of the
new AEDs) more patients have benefited from tradi-
tional rather from new AEDs. The only exception was
the combination LTG/VPA which appears to be an
important innovation.
Despite the expansion of therapeutic options
during the last decade, two thirds of the resident
patients of an epilepsy centre are not seizure free,
further innovation is urgently needed.
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